Top View
- CHOA Clinical Trial Master List
- Changing Paradigms in Management of Metastatic Castration Resistant Prostate Cancer (Mcrpc) Eva Gupta1*, Troy Guthrie2 and Winston Tan1
- Known Bioactive Library: Selleck Bioactive 10Mm, 3.33Mm, 1.11Mm
- Galeterone for the Treatment of Advanced Prostate Cancer: the Evidence to Date
- Annexure‐ I : Specifications of FDA Approved Drug Library
- Targeting Androgen Receptor Versus Targeting Androgens to Suppress Castration Resistant Prostate Cancer
- Product List
- WO 2016/170102 Al 27 October 2016 (27.10.2016) P O P C T
- | Hao Wakati Mwith a Man Tai Ole
- GSK3B Regulates Epithelial-Mesenchymal Transition and Cancer Stem Cell Properties and Is a Novel Drug Target for Triple-Negative Breast Cancer
- Essai Clinique Généré Le 27 Sept
- Androgen Receptor Antagonism Drives Cytochrome P450 17A1 Inhibitor Efficacy in Prostate Cancer
- Therapeutic Rationales, Progresses, Failures, and Future Directions for Advanced Prostate Cancer Kristine M Wadosky, Shahriar Koochekpour
- Identification of Galeterone and Abiraterone As Inhibitors of Dehydroepiandrosterone Sulfonation Catalyzed by Human Hepatic Cytosol, SULT2A1, Sult2b1b, and SULT1E1 S
- Eighty Years of Targeting Androgen Receptor Activity in Prostate Cancer: the Fight Goes On
- Cancer Therapy: Clinical [Uninvited] Running Title: Galeterone for Metastatic Castration Resistant Prostate Cancer
- Molecular Basis of Drug Resistance and Insights for New Treatment
- Androgen Deprivation and Immunotherapy for the Treatment Of
- Clicktozoomintothepdf
- Androgen Regulates SARS-Cov-2 Receptor Levels and Is Associated with Severe COVID-19 Symptoms in Men
- Determination of Novel Metabolites of Therapeutic
- The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
- An Overview of Next-Generation Androgen Receptor-Targeted Therapeutics in Development for the Treatment of Prostate Cancer
- Androgen Receptor Antagonism Drives Efficacy of CYP17 Inhibitors in CRPC
- Clinical Relevance of Androgen Receptor Alterations in Prostate Cancer
- The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
- TOKAI PHARMACEUTICALS, INC. (Exact Name of Company As Specified in Charter)
- Androgen Receptor Targeted Therapies in Castration&
- Cphi & P-MEC China Exhibition List展商名单version版本20180308
- Cphi & P-MEC China Exhibition List展商名单version版本20180307
- Inhibiting Steroid Biosynthesis in Prostate Cancer
- Galeterone Prevents Androgen Receptor Binding to Chromatin and Enhances Degradation of Mutant Androgen Receptor
- Determination of Novel Metabolites of Therapeutic Agents Used in the Treatment of Castration-Resistant Prostate Cancer